Navigation Links
Bon MOT: Innovative atom trap catches highly magnetic atoms
Date:4/2/2008

A research team from the National Institute of Standards and Technology (NIST) and the University of Maryland has succeeded in cooling atoms of a rare-earth element, erbium, to within two millionths of a degree of absolute zero using a novel trapping and laser cooling technique. Their recent report* is a major step towards a capability to capture, cool and manipulate individual atoms of erbium, an element with unique optical properties that promises highly sensitive nanoscale force or magnetic sensors, as well as single-photon sources and amplifiers at telecommunications wavelengths. It also may have applications in quantum computing devices.

The strongly counterintuitive technique of laser cooling to slow down atoms to very low speedstemperatures close to absolute zerohas become a platform technology of atomic physics. Laser cooling combined with specially arranged magnetic fieldsa so-called magneto-optical trap (MOT)has enabled the creation of Bose-Einstein condensates, the capture of neutral atoms for experiments in quantum computing and ultra-precise time-keeping and spectroscopy experiments. The technique originally focused on atoms that were only weakly magnetic and had relatively simple energy structures that could be exploited for cooling, but two years ago a NIST team showed that the far more complex energy structures of erbium, a strongly magnetic element, also could be manipulated for laser cooling.

The typical MOT uses a combination of six tuned laser beams converging on a point that is in a low magnetic field but surrounded by stronger fields. Originally, the lasers were tuned near a strong natural energy oscillation or resonance in the atom, a condition that provides efficient cooling but to only moderately low temperatures. In the new work, the research team instead used much gentler forces applied through a very weak resonance in order to bring erbium atoms to within a few millionths of a degree of absolute zero. Such wea
'/>"/>

Contact: Michael Baum
michael.baum@nist.gov
301-975-2763
National Institute of Standards and Technology (NIST)
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
3. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
4. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
5. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
6. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
7. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug
8. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
9. A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Bon MOT: Innovative atom trap catches highly magnetic atoms
(Date:5/29/2015)... NEW YORK , May 29, 2015 /PRNewswire/ ... a specialty pharmaceutical and medical device company focused ... of primary and metastatic liver cancers, announces that ... the treatment of uveal melanoma patients with hepatic ... Delivery System, were highlighted in an on-line abstract ...
(Date:5/29/2015)... 29, 2015  Caris Life Sciences ® , ... promise of precision medicine, today announced the presentation ... clinical utility of Caris Molecular Intelligence ® , ... helping to identify targeted treatment options for patients ... the studies, results of which are to be ...
(Date:5/29/2015)... WISCONSIN (PRWEB) May 29, 2015 Results ... virus talimogene laherparepvec and its ability to reduce the ... treatment have been published in the Journal of Clinical ... patients with stages IIIB, IIIC and IV melanoma, a ... of the study was to evaluate the safety and ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ... and Companies"  to their offering.  ... remains a challenge in management. With nearly ... the seven major markets of the world ...
Breaking Biology Technology:Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... ... ... var ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } ...
... 2010 The clinical trials program at UC San ... recognized educational programs of its kind in the world, ... Trials Administration in Latin America Certificate. Classes ... experience. Medica Sur, one of the most respected physician/research ...
... 30, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Biology Technology:Biovista Announces a Drug Repositioning Collaboration With Pfizer 2Biovista Announces a Drug Repositioning Collaboration With Pfizer 3Biovista Announces a Drug Repositioning Collaboration With Pfizer 4Biovista Announces a Drug Repositioning Collaboration With Pfizer 5Biovista Announces a Drug Repositioning Collaboration With Pfizer 6Biovista Announces a Drug Repositioning Collaboration With Pfizer 7Biovista Announces a Drug Repositioning Collaboration With Pfizer 8UC San Diego Offers New Certificate for Clinical Trials Administration in Latin America 2ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 2ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 3ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 4ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 5ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 6ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 7ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 8ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 9ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 10ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 11ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 12ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 13ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 14ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 15ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 16ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 17ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 18ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 19ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 20ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 21ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 22ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 23ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 24ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 25ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 26ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 27ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 28
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
(Date:5/28/2015)... 28, 2015 Industry analyst firm n-tech ... report titled "Markets for Self-Healing Materials: 2015-2022." According to ... and vascular systems, biomaterials, relevant shape memory materials ... $2.7 billion by 2020. The report ... of smart materials. Other recent n-tech reports have included ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... in which the circulating strains of influenza showed genetic ... flu shot was found to be effective in preventing ... vaccine also prevented illnesses but was less effective. , ... infection, a University of Michigan study found. , ...
... Muscle weakness and fiber deterioration seen in muscular dystrophy ... under study for their effects against cancer, a Burnham ... on the potential use of these drugs, called histone ... muscles, thereby countering the progression of the disease, in ...
... an innovative new project being developed by Central Queensland ... around the country could soon have access to rehabilitation ... than having to travel to special outpatient clinics. , ... on-line outpatient rehabilitation service for people who have had ...
Cached Biology News:Flu shot effective against drifted influenza, nasal spray vaccine less so 2Flu shot effective against drifted influenza, nasal spray vaccine less so 3Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy 2
...
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
Biology Products: